The prevalence of respiratory diseases is continuing to increase globally, and according to the data disclosed in the Lancet, respiratory diseases have become the third largest chronic disease in China. According to the statistics of the World Health Organization, respiratory diseases, mainly asthma and chronic obstructive pulmonary disease (COPD), have become one of the top five causes of death both in China and worldwide. With China's diagnosis and treatment rate and control rate gradually moving closer to the United States, the patient base continues to accumulate, the global asthma and COPD drug market sales in 2022 reached 87.403 billion yuan, with the proportion of inhaled preparations in respiratory system drugs steadily increasing, the market is expected to reach 106.967 billion yuan by 2028. The compound annual growth rate (CAGR) was 3.46%.
The markets for inhalational drugs are supposed to grow rapidly over the next decade as the incidence of COPD, asthma and other respiratory diseases keeps increasing. However, due to the high technical barriers of inhalational drugs on R&D, especially manufacturing and quality control, safety assessment and regulatory approval rate, it is difficult to see the "patent cliff". Even under this condition, we have seen the thriving R&D in inhalational drugs in China recent years. How to adopt the new technology rapidly and how to prompt the R&D process and get breakthrough have been the focus of the industry and research institutions.
The “International Symposium on Inhalational Drug R&D" to be held online on September 9-10 is aimed at providing an international platform for the discussion of inhalational drug R&D, specifically focus on Toxicology, BE Studies, Applied Pharmacology and Clinical Research. This symposium will gather the outstanding professionals including government regulatory reviewers (USFDA and China NMPA), research scientists, medical doctors and practitioners, industrial experts and students to share their ideas and their experiences.

For more information